timisstuck
@timisstuck
Followers
2K
Following
11K
Media
558
Statuses
6K
Executive Editor at Life Science Alliance: https://t.co/RCS3L4PRC9 Now with even less Musk: https://t.co/C7i7rnBOT0
New York, NY
Joined June 2008
I tried to cram a lot into this little editorial! Excited and grateful to be in this role, and (dare I say) optimistic for the future.
In this editorial, our new Executive Editor Tim Fessenden shares his vision for the journal. In the midst of systemic and concerning changes in biological and biomedical research, LSA strives to lower barriers to publication & meet authors where they are.
0
0
4
Meanwhile over here in our universe we have (had?) the NIH Directors Award… and MIRA…
0
0
1
Important history!!.
Explore the history of cancer immunotherapy over the last 100+ years, from early observations to modern breakthroughs, and discover its transformative ability in the fight against cancer, in The History of Cancer Immunotherapy: #Immunotherapy.
0
1
1
I always repost tertiary lymphoid structures 🙌.
Grateful for being a part of this story!.
0
0
0
RT @czbiohub: 🚫 No dyes. No bleaching. 🔬 Just AI + label-free microscopy = vivid virtually stained images. New in @NatMachIntell: A deep le….
0
85
0
But again. LISTEN to it. You learn a lot when people explain ~their~ vision of what they are doing. If reality actually resembled Battacharya's version, I would be like 20% mad not 100% mad. If you know a Huberman fan, please please engage them.
1
0
0
At 2:42:00 Battacharya describes how NIH priorities changed in 2021 which reduced his research funding. I'm going to take a wild guess that this change in funding did not abruptly halt congressionally approved research grants with no warning/recourse.
1
0
1
This came out on June 9th (unclear when it was recorded). They talk about boosting support for early career researchers, funding high risk/high reward ideas, promoting replication studies, etc. This while overseeing the largest and most disruptive cuts to funding ever seen.
1
0
0
The NIH and research support that is described here is completely unrecognizable. Like entering a different universe. Faculty, postdocs, grad students, everyone: LISTEN to how Battacharya frames his leadership of NIH when he's on very friendly turf/held to account on nothing.
The new @NIHDirector_Jay wants to revise certain aspects of @NIH to focus on bolder hypotheses & more support for early & mid career scientists. This & solutions to other challenging aspects of publicly funded research (eg, replication crisis) on Huberman Lab podcast out now:
1
0
2
And once editors make this clear to ourselves, it needs to be communicated to authors and readers!.
0
0
1
Editors must have a VERY clear understanding of what exactly journals offer, in a world where when preprints can be both peer reviewed and collected/disseminated. Mandatory listening for the latest on this + a brief history of BioRxiv, + general thoughtfulness of Richard.
Podcast: conversation with me on getting into science, getting out of academia, and pushing change in publishing to adoption of preprints.
2
2
2
RT @MishaTeplitskiy: AI company founders: we won't need human scientists starting tomorrow. AI:
0
1
0
This is cool.
0
0
0
Thoughtful piece on the drive for skepticism vs the baseline requirement of trust in publishing (and research more broadly), from @cenmag .
1
0
0
Filament stop being so weird!! Please come back to just being a fun actin crosslinker for the cytoskeleton folks. 😭😭😭.
Filamin A mRNA can be posttranscriptionally modified by adenosine (A) to inosine (I) editing, causing a glutamate (Q) to an arginine (R) change in the protein. This editing in myeloid cells protects mice from colitis.
0
0
3
One of the final papers I handled over at JCB 🥲.Very happy for these authors linking metabolism with outgrowth of micro metastases!.
Gounis, @CassieJClarke et al. show that cells that seed early lung #metastasis in #BreastCancer have altered metabolism. These metabolic alterations lead them to release extracellular vesicles which engender a microenvironment conducive to invasive growth.
0
3
12
Immunotherapy trials like this teach us sooo much about human immunology/chronobiology.
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
0
0
1